Race, obesity, and risk for prostate cancer

By using data from the prospective SELECT trial (the Selenium and Vitamin E Cancer Prevention Trial, conducted between 2001 and 2011), researchers have been able to suggest that obesity is strongly associated with increased risk for prostate cancer diagnosis among African American males compared to non-Hispanic whites. … READ MORE …

Are prostate cancer-specific mortality rates in Australia higher than they should be?

An article just published in the World Journal of Urology has suggested that rates of prostate cancer-specific mortality in Australia seem to have been unexpectedly higher than in the USA. … READ MORE …

New data on 5-ARI treatment in prevention of and and risk for prostate cancer

A new article in the journal JAMA Oncology has again suggested that the use of 5α-reductase inhibitors (5-ARIs) like finasteride/Proscar and dutasteride/Avodart is not, in fact, associated with any significant risk for clinically significant prostate cancer let alone risk for prostate cancer-specific mortality. … READ MORE …

Correlating baseline PSA levels to future 10-year risk of prostate cancer diagnosis

A new paper in the Journal of Urology represents an initial attempt, based on a prospective, multi-ethnic cohort of nearly 3,000 men, to determine whether baseline PSA levels can predict, with a high level of reliability, subsequent risk for and consequential diagnosis of prostate cancer. … READ MORE …

A completely new test for risk of prostate cancer? But is it good enough?

New data published in the journal Applied Materials and Interfaces (along with media information that should be read with some caution) suggests the possibility of a new way to test for risk of prostate cancer based on the adhesion of citrate-capped gold nanoparticles to biomolecules in truly tiny blood samples. … READ MORE …

Biochemical recurrence among pT2 patients with a positive surgical margin post-surgery

A new paper by a group of German researchers and clinicians has provided us with expanded insight into risk for biochemical recurrence for men with organ-confined prostate cancer and a positive surgical margin based on their post-surgical pathology report. … READ MORE …

Prostate cancer screening said to be “not cost effective”

A new review article in Future Oncology has suggested that

even when based on favorable randomized controlled trials in younger age groups, prostate cancer screening is still not cost effective.

… READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,257 other followers